SWTX SpringWorks Therapeutics, Inc.

Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

$66.22  -4.64 (-6.55%)
As of 12/03/2021 15:59:54 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/04/1999
Outstanding shares:  49,249,215
Average volume:  316,436
Market cap:   $3,489,799,375
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    85205L107
ISIN:        US85205L1070
Sedol:      BGMGM89
Valuation   (See tab for details)
PE ratio:   -46.04
PB ratio:   6.91
PS ratio:   0.00
Return on equity:   -25.25%
Net income %:   -33,572,079.75%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy